纳斯达克一家上市公司将在BTC中收购10亿美元

又有一家纳斯达克公司上市公司宣布，该公司将参加具有里程碑意义的1亿美元比特币（BTC）的独家谈判。

One More Nasdaq Listed Company Has Announced It Is Entering Exclusive Negotiations for a Landmark Acquisition of $1 Billion in Bitcoin (BTC).

又有一家纳斯达克公司上市公司宣布，该公司将参加具有里程碑意义的10亿美元比特币（BTC）的独家谈判。

This step will see Basel Medical Group Ltd (Nasdaq: BMGL) diversify its treasury reserves significantly while allowing the company to maintain its primary focus on expanding its medical services across Asia. The move marks a strategic financial initiative aimed at bolstering its balance sheet and supporting its ambitious growth in high-demand healthcare markets.

此步骤将使巴塞尔医学集团有限公司（NASDAQ：BMGL）多样化其财政部储备，同时允许该公司保持其主要关注的关注，以扩大在亚洲的医疗服务。此举标志着旨在加强资产负债表并支持其在高需求医疗保健市场的雄心勃勃的增长的战略财务主动性。

The company is currently in advanced talks with a consortium of institutional investors and high-net-worth individuals within the cryptocurrency sector. Through an innovative share-swap arrangement, BMGL plans to acquire the $1 billion in Bitcoin. If successful, this acquisition will be one of the largest corporate balance sheet improvements in the Asia-Pacific healthcare industry.

该公司目前正在加密货币领域内与机构投资者和高净值个人的财团进行高级会谈。 BMGL通过创新的股票交易安排，计划收购10亿美元的比特币。如果成功，此次收购将是亚太医疗保健行业最大的公司资产负债表改进之一。

The proposed BTC acquisition will provide multiple strategic benefits to BMGL:

拟议的BTC收购将为BMGL提供多种战略利益：

BMGL will be positioned as a well-capitalized player in emerging Asian healthcare markets, with increased resources for expansion.

BMGL将被定位为新兴亚洲医疗保健市场的资本良好的参与者，并增加了扩张资源。

This acquisition aligns with BMGL's commitment to exploring cutting-edge financial instruments and technologies.

这项收购与BMGL致力于探索最先进金融工具和技术的承诺相吻合。

The move is anticipated to generate significant interest from investors and the financial press, enhancing BMGL's visibility and brand recognition.

预计此举将引起投资者和金融媒体的重大兴趣，从而增强了BMGL的知名度和品牌认可。

The acquisition is expected to be finalized by the end of the current quarter, pending standard closing conditions and any required regulatory approvals.

预计收购将在本季度结束时完成，以待决结束条件和任何要求的监管批准。

“We are excited about the potential of this $1 billion acquisition to provide us with the unprecedented financial capacity to drive our growth strategy in Asia, all while maintaining disciplined financial management,” said Dr. Darren Chhoa, CEO of Basel Medical Group.

巴塞尔医疗集团首席执行官达伦·乔亚（Darren Chhoa）博士说：“我们为这笔10亿美元收购的潜力为我们提供了前所未有的财务能力来推动我们在亚洲的增长战略，同时维持纪律严明的财务管理。”

“This will strengthen our balance sheet and position us for swift execution as we capitalize on strategic opportunities to build a leading healthcare platform across the high-growth Asian markets.”

“这将加强我们的资产负债表并将我们定位为迅速执行，因为我们利用了在高增长亚洲市场上建立领先的医疗平台的战略机会。”

The company will keep investors informed of any material developments in due course.

该公司将在适当的时候向投资者通报任何重大发展。